Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.

Schlesinger N, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, Arulmani U, Sallstig P, So A.

Arthritis Res Ther. 2011 Mar 25;13(2):R53. doi: 10.1186/ar3297.

2.

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.

So A, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, Arulmani U, Sallstig P, Schlesinger N.

Arthritis Rheum. 2010 Oct;62(10):3064-76. doi: 10.1002/art.27600.

3.

Interleukin-1 inhibitors for acute gout.

Sivera F, Wechalekar MD, Andrés M, Buchbinder R, Carmona L.

Cochrane Database Syst Rev. 2014 Sep 1;(9):CD009993. doi: 10.1002/14651858.CD009993.pub2. Review.

PMID:
25177840
4.

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.

Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, Krammer G, Murphy V, Richard D, So AK.

Ann Rheum Dis. 2012 Nov;71(11):1839-48. doi: 10.1136/annrheumdis-2011-200908. Epub 2012 May 14.

PMID:
22586173
5.

Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures.

Hirsch JD, Gnanasakthy A, Lale R, Choi K, Sarkin AJ.

Int J Clin Pract. 2014 Dec;68(12):1503-7. doi: 10.1111/ijcp.12521. Epub 2014 Oct 9.

PMID:
25298264
6.

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.

Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, Balfour A, Krammer G, Sallstig P, So A.

Ann Rheum Dis. 2011 Jul;70(7):1264-71. doi: 10.1136/ard.2010.144063. Epub 2011 May 3.

7.

Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence.

Bardin T.

Joint Bone Spine. 2015 Oct;82 Suppl 1:eS9-16. doi: 10.1016/S1297-319X(15)30003-8. Review.

PMID:
26717801
8.

Difficult-to-treat gouty arthritis: a disease warranting better management.

Schlesinger N.

Drugs. 2011 Jul 30;71(11):1413-39. doi: 10.2165/11592290-000000000-00000. Review.

PMID:
21812506
9.

Canakinumab: a guide to its use in acute gouty arthritis flares.

Lyseng-Williamson KA.

BioDrugs. 2013 Aug;27(4):401-6. doi: 10.1007/s40259-013-0037-2. Review.

PMID:
23649936
10.

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.

Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, Ferreira A, Lheritier K, Patel N, Preiss R, Hawkins PN; Canakinumab in CAPS Study Group.

Arthritis Res Ther. 2011;13(6):R202. doi: 10.1186/ar3535. Epub 2011 Dec 9.

11.

Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis.

Chakraborty A, Van LM, Skerjanec A, Floch D, Klein UR, Krammer G, Sunkara G, Howard D.

J Clin Pharmacol. 2013 Dec;53(12):1240-51. doi: 10.1002/jcph.162. Epub 2013 Sep 30.

PMID:
24122883
12.

Non-steroidal anti-inflammatory drugs for acute gout.

van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewé RB.

Cochrane Database Syst Rev. 2014 Sep 16;(9):CD010120. doi: 10.1002/14651858.CD010120.pub2. Review.

PMID:
25225849
13.
14.

An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial.

Bodick N, Lufkin J, Willwerth C, Kumar A, Bolognese J, Schoonmaker C, Ballal R, Hunter D, Clayman M.

J Bone Joint Surg Am. 2015 Jun 3;97(11):877-88. doi: 10.2106/JBJS.N.00918.

PMID:
26041848
15.

Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis.

Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ.

J Rheumatol. 1993 Jan;20(1):111-3.

PMID:
8441139
17.
18.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group.

N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.

PMID:
28845751
19.

Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.

Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, King-Davis S, Weinstein SP.

Arthritis Res Ther. 2013 Feb 1;15(1):R25. doi: 10.1186/ar4159.

20.

Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus.

Noe A, Howard C, Thuren T, Taylor A, Skerjanec A.

Clin Ther. 2014 Nov 1;36(11):1625-37. doi: 10.1016/j.clinthera.2014.08.004. Epub 2014 Sep 18.

Supplemental Content

Support Center